- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05748613
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's (ASTRA)
Treatment of Stress and Anxiety in Mild Cognitive Impairment/Mild Alzheimer's Disease and Related Dementias - RCT
The goal of this clinical trial is to test the effectiveness of a computerized anxiety sensitivity treatment (CAST) compared to a health education control (HEC) in older adults with mild cognitive impairment (MCI) or mild Alzheimer's Disease and related dementias (ADRD) and their care partners. The main questions it aims to answer are:
- Efficacy of CAST in reducing anxiety and related symptoms among those with MCI/mild ADRD
- Efficacy of CAST in reducing care partner burden among care partners of people living with MCI/mild ADRD
- Explore treatment mechanisms using a multi-modal assessment battery of anxiety sensitivity and anxiety
Participants will complete six in-person visits including a baseline assessment, two intervention sessions, and three follow-up assessments at 1, 3, and 6-months posttreatment. Participants will also complete three weeks of ecological momentary assessments (EMAs) for one week prior to intervention, one week between intervention sessions, and one week after intervention.
If there is a comparison group: Researchers will compare CAST to HEC to see if CAST reduces anxiety and related symptoms in older adults with MCI/mild ADRD and care partner burden to a greater degree than HEC.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Norman B Schmidt, Ph.D.
- Phone Number: 8506451766
- Email: schmidt@psy.fsu.edu
Study Contact Backup
- Name: Frederick T Schubert, B.A.
- Phone Number: 8045439845
- Email: schubert@psy.fsu.edu
Study Locations
-
-
Florida
-
Tallahassee, Florida, United States, 32306
- Recruiting
- Anxiety and Behavioral Health Clinic
-
Principal Investigator:
- Norman B. Schmidt, Ph.D.
-
-
Ohio
-
Athens, Ohio, United States, 45701
- Recruiting
- Ohio University
-
Contact:
- Nik Allan, PhD
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University
-
Contact:
- Nik Allan, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
DYAD
- Patient age 60+
- Care partner 18+
- Has care partner who will participate ("someone you have a reciprocal relationship with who provides you with emotional or physical support and helps with decision-making. This could be a spouse or significant other, relative, or close friend whom you spend a significant amount of time with.")
- Has smartphone or access to Wi-Fi
EITHER
- Score of 20 or above on the PROMIS-Anxiety short form (patient only) OR
- Score of 5 or above on SSASI (patient only) OR
- Score of 31 or above on NIH Toolbox Perceived Stress Scale score (patient only)
AND EITHER
Participant MoCA score is between 17 to 26
OR
Participant Memory Complaint Scale score 3 or greater
OR
- Care partner quick dementia rating scale score between 2 to 12.5
Exclusion Criteria:
PATIENT
- Issues with seeing or hearing that would prevent reading or listening to computer presentations
- Medical conditions that would preclude participation in study
- Severe mental illness (e.g., schizophrenia, unmedicated bipolar disorder)
CARE PARTNER
- Issues with seeing or hearing that would prevent reading or listening to computer presentations
- Medical conditions that would preclude participation in study
- Severe mental illness (e.g., schizophrenia, unmedicated bipolar disorder)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Computerized Anxiety Sensitivity Treatment
CAST is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated anxiety sensitivity (AS), particularly the amplification of cognitive stress symptoms including perceived confusion and memory problems.
CAST is a fully computerized, 1-hour intervention containing video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension, introduction and practice with interoceptive exposures).
Procedures draw heavily on standard CBT techniques; AS, a core vulnerability for anxiety and depression is targeted using these procedures.
In CAST, participants are informed that "the primary purpose of the presentation is to highlight healthier, more productive, and effective ways of dealing with stress."
Through participation in the intervention, people learn adaptive long-term strategies for tolerating, coping with, and effectively reducing distress and negative emotions.
|
Brief computerized treatment for anxiety sensitivity
Other Names:
|
|
Placebo Comparator: Health Education Control
HEC is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors.
Content includes healthy eating, hydration, sleep and rest, exercise, stress management as well as other healthy lifestyle tips.
To match the interactive components in the CAST condition, behavior tracking and goal-setting are included in HEC.
The HEC protocol has been used in prior studies as a control condition for CAST to account for intervention modality and time.
HEC is perceived positively, with high rates of acceptability.
Importantly, HEC is inert with respect to the proposed mechanism of action (AS).
|
Brief computerized presentation on healthy behaviors
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in anxiety sensitivity pre intervention to posttreatment.
Time Frame: Baseline to immediately after the intervention
|
Anxiety sensitivity will be measured using the Anxiety Sensitivity Index-3 (ASI-3).
The ASI-3 is an 18-item self report measure with possible scores ranging from 0 to 72.
Higher scores indicate higher anxiety sensitivity.
|
Baseline to immediately after the intervention
|
|
Change in anxiety pre intervention to 1-month follow-up.
Time Frame: Baseline to 1-month follow-up
|
Anxiety will be assessed using the Patient-Reported Outcomes Measurement Information System - Anxiety (PROMIS Anxiety) Short Form 8a self-report measure.
The PROMIS Anxiety is an 8-item self report questionnaire with possible scores ranging from 8 to 40.
Higher scores indicate more anxiety.
|
Baseline to 1-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in negative affect pre intervention to 1-month follow-up.
Time Frame: Baseline to 1-month follow-up
|
Negative affect will be assessed using the Positive and Negative Affect Schedule - Negative Affect (PANAS-NA).
PANAS-NA is a 10-item self-report measure with possible scores ranging from 10 to 50.
Higher scores indicate more negative affect.
|
Baseline to 1-month follow-up
|
|
Change in stress pre intervention to 1-month follow-up.
Time Frame: Baseline to 1-month follow-up
|
Stress will be assessed with the NIH Toolbox - Perceived Stress.
The NIH Toolbox - Perceived Stress is a 10-item self-report measure with possible scores ranging from 10 to 50.
Higher scores indicate more stress.
|
Baseline to 1-month follow-up
|
|
Change in quality of life pre intervention to 1-month follow-up.
Time Frame: Baseline to 1-month follow-up
|
Quality of life will be assessed with the NIH Toolbox General Life Satisfaction scale.
The NIH Toolbox General Life Satisfaction scale is a 5-item self-report measure with possible scores ranging from 5 to 35.
Higher scores indicate higher life satisfaction.
|
Baseline to 1-month follow-up
|
|
Change in depression pre intervention to 1-month follow-up.
Time Frame: Baseline to 1-month follow-up
|
Depression will be assessed using the PROMIS - Depression Short Form 8b.
The PROMIS - Depression is an 8-item self-report measure with possible scores ranging from 8 to 40.
Higher scores indicate higher level of depression.
|
Baseline to 1-month follow-up
|
|
Change in cognitive functioning pre intervention to 1-month follow-up.
Time Frame: Baseline to 1-month follow-up
|
Cognitive functioning will be assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
RBANS assesses cognitive functioning in the following domains: immediate memory, visuospatial functioning, attention, language, and delayed memory.
|
Baseline to 1-month follow-up
|
|
Stability of anxiety sensitivity from posttreatment to 6-month follow-up.
Time Frame: Immediately after the intervention to 6-month follow-up.
|
Anxiety sensitivity will be measured using the Anxiety Sensitivity Index-3 (ASI-3).
The ASI-3 is an 18-item self report measure with possible scores ranging from 0 to 72.
Higher scores indicate higher anxiety sensitivity.
|
Immediately after the intervention to 6-month follow-up.
|
|
Stability of anxiety from 1-month follow-up to 6-month follow-up.
Time Frame: 1-month to 6-month follow-up
|
Anxiety will be assessed using the Patient-Reported Outcomes Measurement Information System - Anxiety (PROMIS Anxiety) Short Form 8a self-report measure.
The PROMIS Anxiety is an 8-item self report questionnaire with possible scores ranging from 8 to 40.
Higher scores indicate more anxiety.
|
1-month to 6-month follow-up
|
|
Stability of depression from 1-month follow-up to 6-month follow-up.
Time Frame: 1-month to 6-month follow-up
|
Depression will be assessed using the PROMIS - Depression Short Form 8b.
The PROMIS - Depression is an 8-item self-report measure with possible scores ranging from 8 to 40.
Higher scores indicate higher level of depression.
|
1-month to 6-month follow-up
|
|
Stability of negative affect from 1-month follow-up to 6-month follow-up.
Time Frame: 1-month to 6-month follow-up
|
Negative affect will be assessed using the Positive and Negative Affect Schedule - Negative Affect (PANAS-NA).
PANAS-NA is a 10-item self-report measure with possible scores ranging from 10 to 50.
Higher scores indicate more negative affect.
|
1-month to 6-month follow-up
|
|
Stability of stress from 1-month follow-up to 6-month follow-up.
Time Frame: 1-month to 6-month follow-up
|
Stress will be assessed with the NIH Toolbox - Perceived Stress.
The NIH Toolbox - Perceived Stress is a 10-item self-report measure with possible scores ranging from 10 to 50.
Higher scores indicate more stress.
|
1-month to 6-month follow-up
|
|
Stability of quality of life from 1-month follow-up to 6-month follow-up.
Time Frame: 1-month to 6-month follow-up
|
Quality of life will be assessed with the NIH Toolbox General Life Satisfaction scale.
The NIH Toolbox General Life Satisfaction scale is a 5-item self-report measure with possible scores ranging from 5 to 35.
Higher scores indicate higher life satisfaction.
|
1-month to 6-month follow-up
|
|
Stability of cognitive functioning from 1-month follow-up to 6-month follow-up.
Time Frame: 1-month to 6-month follow-up
|
Cognitive functioning will be assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
RBANS assesses cognitive functioning in the following domains: immediate memory, visuospatial functioning, attention, language, and delayed memory.
|
1-month to 6-month follow-up
|
|
Change in care partner burden from pre intervention to 1-month follow-up.
Time Frame: Baseline to 1-month follow-up
|
Care partner burden will be assessed using the Zarit Burden Interview - Short.
The Zarit Burden Interview - Short is a 12-item self-report questionnaire with a possible score range of 0 to 48.
Higher scores indicate higher burden levels.
|
Baseline to 1-month follow-up
|
|
Change in objective measure of interoceptive fear conditioning pre to posttreatment
Time Frame: Baseline to immediately after the intervention
|
Interoceptive fear conditioning will be assessed with a skin conductance response (SCR) during an interoceptive exposure.
Higher SCR numbers indicate higher interoceptive fear.
|
Baseline to immediately after the intervention
|
|
Change in Loneliness from pre intervention to 1-month follow up
Time Frame: Baseline through Month 1 follow up
|
Loneliness will be measured using the 10-item UCLA Loneliness Short form questionnaire.
This self-report scale yields scores between 10 to 40 with higher scores indicating more significant loneliness symptoms.
|
Baseline through Month 1 follow up
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063.
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57.
- Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86. doi: 10.1016/s0005-7916(00)00012-4.
- Attkisson CC, Zwick R. The client satisfaction questionnaire. Psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann. 1982;5(3):233-7. doi: 10.1016/0149-7189(82)90074-x.
- Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997 May;48(5 Suppl 6):S10-6. doi: 10.1212/wnl.48.5_suppl_6.10s.
- Zarit, S., Orr, N. K., & Zarit, J. M. (1985). The hidden victims of Alzheimer's disease: Families under stress. NYU press.
- Galvin JE. THE QUICK DEMENTIA RATING SYSTEM (QDRS): A RAPID DEMENTIA STAGING TOOL. Alzheimers Dement (Amst). 2015 Jun 1;1(2):249-259. doi: 10.1016/j.dadm.2015.03.003.
- Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9. doi: 10.1076/jcen.20.3.310.823.
- Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982 Jun;140:566-72. doi: 10.1192/bjp.140.6.566.
- Kupst MJ, Butt Z, Stoney CM, Griffith JW, Salsman JM, Folkman S, Cella D. Assessment of stress and self-efficacy for the NIH Toolbox for Neurological and Behavioral Function. Anxiety Stress Coping. 2015;28(5):531-44. doi: 10.1080/10615806.2014.994204. Epub 2015 Feb 10.
- Taylor S, Zvolensky MJ, Cox BJ, Deacon B, Heimberg RG, Ledley DR, Abramowitz JS, Holaway RM, Sandin B, Stewart SH, Coles M, Eng W, Daly ES, Arrindell WA, Bouvard M, Cardenas SJ. Robust dimensions of anxiety sensitivity: development and initial validation of the Anxiety Sensitivity Index-3. Psychol Assess. 2007 Jun;19(2):176-88. doi: 10.1037/1040-3590.19.2.176.
- Zvolensky MJ, Garey L, Fergus TA, Gallagher MW, Viana AG, Shepherd JM, Mayorga NA, Kelley LP, Griggs JO, Schmidt NB. Refinement of anxiety sensitivity measurement: The Short Scale Anxiety Sensitivity Index (SSASI). Psychiatry Res. 2018 Nov;269:549-557. doi: 10.1016/j.psychres.2018.08.115. Epub 2018 Aug 29.
- Vale FAC, Balieiro AP Jr, Silva-Filho JH. Memory complaint scale (MCS). Proposed tool for active systematic search. Dement Neuropsychol. 2012 Oct-Dec;6(4):212-218. doi: 10.1590/S1980-57642012DN06040004.
- Delis, D. C., Kaplan, E., & Kramer, J. H. (2001). Delis-Kaplan Executive Function System (D-KEFS) [Database record]. APA PsycTests.
- Wechsler, D. (2008). Wechsler Adult Intelligence Scale--Fourth Edition (WAIS-IV) [Database record]. APA PsycTests.
- Hatcher, R. L., & Gillaspy, A. (2006). Working Alliance Inventory-Short Revised [Database record]. APA PsycTests.
- Craig, C., Marshall, A., Sjostrom, M., Bauman, A., Lee, P., Macfarlane, D., ... & Stewart, S. (2017). International physical activity questionnaire-short form. J Am Coll Health, 65(7), 492-501.
- Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.
- Markley AE, Stratton KM, Cho GY, Schmidt NB, Suhr J, Sheffler JL, Nguyen C, Schubert FT, Quiles JRG, Potter MR, Meynadasy MA, Irvin SM, Allan NP. Study design and protocol for cognitive anxiety sensitivity treatment for anxiety in adults with mild cognitive impairment or dementia. Contemp Clin Trials. 2025 Sep;156:108044. doi: 10.1016/j.cct.2025.108044. Epub 2025 Aug 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00003432
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
Benjamin Rose Institute on AgingNational Institute on Aging (NIA)RecruitingMild Dementia | Moderate DementiaUnited States
-
Yaolin PeiNational Institutes of Health (NIH)RecruitingEnd of Life Decision Making | Dementia Caregivers | Advanced DementiaUnited States
-
Benuvia Therapeutics Inc.MandaraNot yet recruiting
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityCompletedDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeActive, not recruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityCompletedDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
The University of Hong KongNot yet recruiting
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
Clinical Trials on Computerized Anxiety Sensitivity Treatment
-
Florida State UniversityCompleted
-
Florida State UniversityCompletedComputerized Anxiety Sensitivity Treatment | Health Education TreatmentUnited States
-
Southeast Louisiana Veterans Health Care SystemSouth Central Mental Illness Research, Education & Clinical CenterCompletedOpioid Use DisorderUnited States
-
Ohio UniversityCompletedAnxiety | Anxiety SensitivityUnited States
-
VA Office of Research and DevelopmentCompleted
-
Florida State UniversityCompletedExperimental | Placebo ContolUnited States
-
Temple UniversityPennsylvania Department of HealthCompleted
-
Florida State UniversityNational Institute of Mental Health (NIMH)Active, not recruiting
-
University of VermontNational Institute on Drug Abuse (NIDA)Completed
-
Florida State UniversityCompletedObsessive-Compulsive Disorder and Symptoms